Fresenius SE & Co. (FSNUY) Stock Price, News & Analysis

Company Overview

Fresenius SE & Co. KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network. The company traces its origins to a pharmacy established by Dr. Eduard Fresenius in Frankfurt in 1912. Michael Sen has served as chief executive officer since 2022.

Key Stats

• Today's Range: $12.27 to $12.61
• 50-Day Range: $12.45 to $13.83
• 52-Week Range: $10.33 to $33.93
• Volume: 655,017 shs
• Average Volume: 81,165 shs
• Market Capitalization: $28.05 billion
• P/E Ratio: 15.76
• Dividend Yield: 1.61%
• Price Target: N/A
• Consensus Rating: Buy

Fresenius SE & Co. Stock Analysis - MarketRank™

Fresenius SE & Co. scored higher than 57% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.9 / 5
• Analyst Rating: Buy

Consensus Rating

Fresenius SE & Co. has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Fresenius SE & Co. has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 6.48%

Earnings Growth

Earnings for Fresenius SE & Co. are expected to grow by 6.48% in the coming year, from $1.08 to $1.15 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Fresenius SE & Co. is 15.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.52.

Price to Earnings Ratio vs. Sector

The P/E ratio of Fresenius SE & Co. is 15.76, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.64.

Price to Book Value per Share Ratio

Fresenius SE & Co. has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Fresenius SE & Co. has been sold short.

Short Interest Ratio / Days to Cover

Fresenius SE & Co. has a short interest ratio ("days to cover") of 0.37, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Fresenius SE & Co. has recently increased by 86.73%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Fresenius SE & Co. pays a meaningful dividend of 1.60%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Fresenius SE & Co. does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Fresenius SE & Co. is 25.32%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Fresenius SE & Co. will have a dividend payout ratio of 17.39% next year. This indicates that Fresenius SE & Co. will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.41

News Sentiment

Fresenius SE & Co. has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Fresenius SE & Co. this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Fresenius SE & Co. insiders have not sold or bought any company stock.

Percentage Held by Institutions

Fresenius SE & Co. has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/01/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: OTCMKTS:FSNUY
• CIK: 904868
• Web: www.fresenius.com
• Phone: (496) 172-6080
• Fax: N/A
• Employees: 178,394
• Year Founded: 1912

Profitability

• EPS (Trailing Twelve Months): $0.79
• Trailing P/E Ratio: 15.76
• Forward P/E Ratio: 11.53
• P/E Growth: N/A
• Net Income: $1.43 billion
• Net Margins: 6.67%
• Pretax Margin: 9.53%
• Return on Equity: 10.25%
• Return on Assets: 4.87%

Debt

• Debt-to-Equity Ratio: 0.41
• Current Ratio: 1.28
• Quick Ratio: 0.97

Sales & Book Value

• Annual Sales: $25.87 billion
• Price / Sales: 1.08
• Cash Flow: $1.54 per share
• Price / Cash Flow: 8.10
• Book Value: $9.93 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: 2,252,950,000
• Free Float: N/A
• Market Cap: $28.05 billion
• Optionable: Not Optionable
• Beta: 0.60